Shingles Vaccine Market Trends

Shingles Vaccine Market Trends

New-generation vaccines, particularly recombinant shingles vaccines, offer high efficacy and have transformed the prevention landscape for herpes zoster (shingles), especially among older adults who are most vulnerable to this disease. Recent developments have addressed past limitations of traditional vaccines, including concerns about weakened immunity in aging populations and adverse effects.
 

• Recombinant shingles vaccines, such as Shingrix, represent a major advancement over earlier live-attenuated vaccines. These vaccines use targeted proteins from the varicella-zoster virus to stimulate immunity without the need for live viruses, making them suitable for individuals with weakened immune systems. Clinical trials have demonstrated that recombinant vaccines offer over 90% efficacy in preventing shingles, even among adults over 60, and have a lower likelihood of triggering adverse effects. This high level of efficacy and safety has led to increased recommendations from health organizations, encouraging more people to opt for vaccination.
   
• Additionally, advances in vaccine technology have resulted in longer-lasting immunity. Earlier shingles vaccines showed a decline in efficacy over time, necessitating consideration of additional doses or boosters. Recombinant vaccines, however, offer improved durability, providing extended protection that is critical for older adults, who may be at higher risk of developing shingles as their immune function naturally declines. This extended immunity reduces the need for frequent revaccination, adding convenience for patients and supporting stronger market demand.